Drug Profile


Alternative Names: LU 23174; S 1991; Serdolect; Serlect

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Lundbeck A/S
  • Class Antipsychotics; Imidazoles; Indoles
  • Mechanism of Action Alpha 1 adrenergic receptor antagonists; Dopamine D2 receptor antagonists; Serotonin 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Schizophrenia

Most Recent Events

  • 13 Aug 2010 Discontinued - Preregistration for Schizophrenia in USA (PO)
  • 25 Jun 2009 Lundbeck receives complete response letter from the US FDA for sertindole in Schizophrenia
  • 08 Apr 2009 Psychopharmacology Drug Advisory Committee issues an opinion on sertindole for Schizophrenia in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top